<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01794507</url>
  </required_header>
  <id_info>
    <org_study_id>M12-901</org_study_id>
    <secondary_id>2011-004626-10</secondary_id>
    <nct_id>NCT01794507</nct_id>
  </id_info>
  <brief_title>A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy</brief_title>
  <official_title>A Phase 1b Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Relapsed or Refractory Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Their Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to assess the safety profile, characterize
      pharmacokinetics (PK) and determine the dosing schedule, maximum tolerated dose (MTD), and
      the recommended phase two dose (RPTD) of ABT-199 when administered in subjects with relapsed
      /refactory multiple myeloma who are receiving bortezomib and dexamethasone as their standard
      therapy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 19, 2012</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of peak concentration (Cmax) of ABT-199</measure>
    <time_frame>Approximately 5 days in Cycle 1 then on Day 1 of Cycles 2,4,6,8</time_frame>
    <description>Blood samples for pharmacokinetic analysis of ABT-199 will be collected at designated timepoints</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine maximum tolerated dose (MTD) of ABT-199</measure>
    <time_frame>Minimum first cycle of dosing (21 days)</time_frame>
    <description>ABT-199 will be dose-escalated until the largest dose is reached that is determined to be safe based on adverse event reporting and dose-limiting toxicities information from all subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>From subject's first dose of ABT-199 until 30 days after subject's last dose of ABT-199; up to 2 years following last subject first dose.</time_frame>
    <description>Collect all adverse events at each visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of trough concentration (Ctrough) of ABT-199</measure>
    <time_frame>Approximately 5 days in Cycle 1 then on Day 1 of Cycles 2,4,6,8</time_frame>
    <description>Blood samples for pharmacokinetic analysis of ABT-199 will be collected at designated timepoints</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of area under the concentration versus time curve (AUC) of ABT-199</measure>
    <time_frame>Approximately 5 days in Cycle 1 then on Day 1 of Cycles 2,4,6,8</time_frame>
    <description>Blood samples for pharmacokinetic analysis of ABT-199 will be collected at designated timepoints</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine recommended phase two dose (RPTD) of ABT-199</measure>
    <time_frame>Minimum first cycle of dosing (21 days</time_frame>
    <description>ABT-199 will be dose-escalated until the largest dose is reached that is determined to be safe based on adverse event reporting and dose-limiting toxicities information from all subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Measured up to 48 months after the last subject has enrolled in the study</time_frame>
    <description>Number of days from the day of initial response is objectively documented to the day that disease progression is objectively documented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Measured up to 48 months after the last subject has enrolled in the study</time_frame>
    <description>The proportion of subjects with response using International Myeloma Working Group (IMWG) response criteria will be computed for all subjects with active disease at baseline (in the opinion of the investigator)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Disease Progression</measure>
    <time_frame>Measured up to 48 months after the last subject has enrolled in the study</time_frame>
    <description>Number of days from the date of the first dose of ABT-199 to the date of the subject's disease progression.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Relapsed/Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>ABT-199 + BTZ/Dex Dose Escalation Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluate the safety and pharmacokinetics profile of ABT-199 administered with standard therapy bortezomib and dexamethasone in a dose escalation scheme in approximately 54 subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-199 + BTZ/Dex Safety Expansion Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Safety expansion cohort to further evaluate recommended phase two dose (RPTD) of ABT-199 administered with standard therapy bortezomib and dexamethasone in approximately 12 subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-199</intervention_name>
    <description>ABT-199 at cohort-defined dosing schedules and dose levels. ABT-199 at defined dose and schedule for Safety Expansion cohort</description>
    <arm_group_label>ABT-199 + BTZ/Dex Dose Escalation Cohorts</arm_group_label>
    <arm_group_label>ABT-199 + BTZ/Dex Safety Expansion Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>Bortezomib at cohort-defined dosing schedules and dose levels. Bortezomib at defined dose and schedule for Safety Expansion cohort</description>
    <arm_group_label>ABT-199 + BTZ/Dex Dose Escalation Cohorts</arm_group_label>
    <arm_group_label>ABT-199 + BTZ/Dex Safety Expansion Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Dexamethasone at cohort-defined dosing schedules and dose levels. Dexamethasone at defined dose and schedule for Safety Expansion cohort.</description>
    <arm_group_label>ABT-199 + BTZ/Dex Dose Escalation Cohorts</arm_group_label>
    <arm_group_label>ABT-199 + BTZ/Dex Safety Expansion Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance score less than or equal to 1

          -  Diagnosis of multiple myeloma previously treated with at least 1 prior line of therapy
             (dose escalation only) or (safety expansion only) received treatment with a proteasome
             inhibitor or an IMiD(r) or immunomodulatory agent (e.g., thalidomide, lenalidomide).
             Induction therapy and following stem cell transplant are considered a single line of
             therapy.

          -  Measurable disease at Screening: Serum monoclonal protein greater than or equal to 1
             g/dL by protein electrophoresis, or greater than or equal to 200 mg monoclonal protein
             in the urine on 24-hr electrophoresis, or serum immunoglobulin free light chain
             greater than or equal to 10 mg/dL and abnormal serum immunoglobulin kappa to lambda
             free light chain ratio.

          -  Subjects with a history of autologous or allogenic stem cell transplant must have
             adequate bone marrow independent of any growth factor support, and have recovered from
             any transplant related toxicity(s); and either greater than 100 days post-autologous
             transplant (prior to first dose of study drug) or greater than or equal to 6 months
             post-allogenic transplant (prior to first dose of study drug) and not have active
             graft-versus-host disease (i.e., requiring treatment).

          -  Subject must have adequate coagulation, renal, and hepatic function, per laboratory
             reference range at Screening.

        Exclusion Criteria:

          -  Exhibits evidence of other clinically significant uncontrolled condition(s),
             including, but not limited to: uncontrolled systemic infection (viral, bacterial, or
             fungal), diagnosis of fever and neutropenia within 1 week prior to first dose of study
             drug

          -  Cardiovascular disability status of New York Heart Association Class greater than or
             equal to 2. Class 2 is defined as cardiac disease in which patients are comfortable at
             rest but ordinary physical activity results in fatigue, palpitations, dyspnea or
             anginal pain.

          -  Significant history of renal, neurologic, psychiatric, endocrinologic, metabolic,
             immunologic, cardiovascular, pulmonary or hepatic disease, that in the opinion of the
             investigator, would adversely affect his/her participation in the study.

          -  History of other active malignancies other than multiple myeloma within the past 3
             years prior to study entry, with the following exceptions: adequately treated in situ
             carcinoma of the cervix uteri, basal cell carcinoma of the skin or localized squamous
             cell carcinoma of the skin, previous malignancy confined and surgically resected (or
             treated with other modalities) with curative intent.

          -  Tested positive for HIV or hepatitis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Arizona Cancer Ctr</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719-1478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2927</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Ctr</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lille - HÃ´pital Claude Huriez</name>
      <address>
        <city>Lille CEDEX</city>
        <state>Hauts-de-France</state>
        <zip>59045</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes, Hotel Dieu -HME</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2012</study_first_submitted>
  <study_first_submitted_qc>February 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2013</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>relapsed/refractory multiple myeloma</keyword>
  <keyword>relapsed multiple myeloma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

